OTCMKTS:ARTH

Arch Therapeutics (ARTH) Stock Forecast, Price & News

$1.30

0.00 (0.00%)

(As of 09/29/2023 08:54 PM ET)

Compare

Today's Range: $1.30
▼
$1.34
50-Day Range: $0.55
▼
$2.60
52-Week Range: $0.48
▼
$10.80

Volume: 600 shs
Average Volume: 1,587 shs
Market Capitalization: $4.02 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Earnings Financials Headlines SEC Filings Short Interest

About Arch Therapeutics (OTCMKTS:ARTH) Stock

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Price History

30 days | 90 days | 365 days | Advanced Chart

ARTH Stock News Headlines

September 13, 2023 | finance.yahoo.com

Arch Therapeutics Provides AC5® Commercialization Update

September 8, 2023 | finanznachrichten.de

Arch Therapeutics, Inc.: Arch Therapeutics Completes Financing as Bridge to Uplisting

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 7, 2023 | finance.yahoo.com

Arch Therapeutics Completes Financing as Bridge to Uplisting

July 8, 2023 | health.usnews.com

Dr. Arth Patel

June 13, 2023 | travel.usnews.com

Double Arch

April 25, 2023 | finance.yahoo.com

Arch Therapeutics to Present AC5® Advanced Wound System at 2023 Symposium on Advanced Wound Care (“SAWC”)

April 5, 2023 | finance.yahoo.com

Dedicated HCPCS Billing Code for Arch Therapeutics’ AC5® Advanced Wound System Now In Effect

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

March 20, 2023 | investing.com

Arch Therapeutics Inc (ARTHD)

March 9, 2023 | finance.yahoo.com

Arch Therapeutics’ AC5® Advanced Wound System Receives Dedicated HCPCS Billing Code from The Centers for Medicare & Medicaid Services

March 7, 2023 | finance.yahoo.com

Arch Therapeutics Announces Addition of Contract Sales Force to Advance Commercialization of AC5® Advanced Wound System in Government Facilities

February 23, 2023 | benzinga.com

Arch Therapeutics Inc Stock (OTC:ARTHD), Earnings Estimates, EPS, and Revenue

January 24, 2023 | msn.com

Wound products developer Arch Therapeutics files for uplisting, $35M offering (update)

January 18, 2023 | finanznachrichten.de

Arch Therapeutics, Inc.: Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange

January 18, 2023 | finance.yahoo.com

Arch Therapeutics Announces Formation of Medical Advisory Board to Advance Commercialization of AC5® Advanced Wound System

January 17, 2023 | finance.yahoo.com

Arch Announces One-for-Two-Hundred Reverse Stock Split in Connection with Application for Uplisting to a National Exchange

December 5, 2022 | finance.yahoo.com

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System

October 20, 2022 | seekingalpha.com

ARTH Arch Therapeutics, Inc.

October 18, 2022 | yahoo.com

Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Fall

October 11, 2022 | finance.yahoo.com

Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall

September 23, 2022 | finance.yahoo.com

Arch Therapeutics Announces First Shipments of AC5® Advanced Wound System Under New Reimbursement Support Program

September 16, 2022 | finance.yahoo.com

Arch Therapeutics Announces Intent to Uplist from OTC to a National Exchange

September 7, 2022 | finance.yahoo.com

Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System

July 14, 2022 | benzinga.com

Arch Therapeutics (OTC:ARTH), Short Interest Report

July 7, 2022 | finance.yahoo.com

Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing

June 22, 2022 | finance.yahoo.com

Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel

See More Headlines

Receive ARTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arch Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTH Company Calendar

Last Earnings: 8/11/2023
Today: 10/02/2023
Next Earnings (Estimated): 12/25/2023
Fiscal Year End: 9/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ARTH
Previous Symbol: NASDAQ:ARTH
CUSIP: N/A
CIK: 1537561
Web: www.archtherapeutics.com
Phone: (617) 431-2313
Fax: N/A
Employees: 8
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-5,280,000.00
Net Margins: -16,959.23%
Pretax Margin: -16,956.59%
Return on Equity: N/A
Return on Assets: -281.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.16
Quick Ratio: 0.02

Sales & Book Value

Annual Sales: $20,000.00
Price / Sales: 200.85
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.36) per share
Price / Book: -0.39

Miscellaneous

Outstanding Shares: 3,090,000
Free Float: 2,955,000
Market Cap: $4.02 million
Optionable: Not Optionable
Beta: 0.65

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Terrence W. Norchi M.D. (Age 58)
Co-Founder, Chairman, Pres & CEO
Comp: $450.5k

Mr. Michael S. Abrams (Age 53)
CFO & Treasurer
Comp: $325k

Mr. Daniel M. Yrigoyen (Age 53)
VP of Sales
Comp: $316.67k

Dr. Rutledge Ellis-Behnke Ph.D.
Co-Founder & Scientific Advisor

Key Competitors

View All Competitors

ARTH Stock - Frequently Asked Questions

How have ARTH shares performed in 2023?: Arch Therapeutics' stock was trading at $0.0260 at the beginning of 2023. Since then, ARTH stock has increased by 4,900.0% and is now trading at $1.30.
View the best growth stocks for 2023 here.
Are investors shorting Arch Therapeutics?: Arch Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 3,700 shares, an increase of 76.2% from the August 31st total of 2,100 shares. Based on an average daily trading volume, of 14,500 shares, the short-interest ratio is presently 0.3 days.
View Arch Therapeutics' Short Interest.
When is Arch Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, December 25th 2023.
View our ARTH earnings forecast.
How were Arch Therapeutics' earnings last quarter?: Arch Therapeutics, Inc. (OTCMKTS:ARTH) announced its quarterly earnings data on Friday, August, 11th. The biotechnology company reported ($1.42) earnings per share (EPS) for the quarter. The biotechnology company earned $0.01 million during the quarter.

What other stocks do shareholders of Arch Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arch Therapeutics investors own include Anavex Life Sciences (AVXL), POET Technologies (POETF), Aptose Biosciences (APTO), Inovio Pharmaceuticals (INO), Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), Bellerophon Therapeutics (BLPH), Sorrento Therapeutics (SRNE), Biocept (BIOC) and Aurinia Pharmaceuticals (AUPH).
What is Arch Therapeutics' stock symbol?: Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
How do I buy shares of Arch Therapeutics?: Shares of ARTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arch Therapeutics' stock price today?: One share of ARTH stock can currently be purchased for approximately $1.30.
How much money does Arch Therapeutics make?: Arch Therapeutics (OTCMKTS:ARTH) has a market capitalization of $4.02 million and generates $20,000.00 in revenue each year.
How can I contact Arch Therapeutics?: Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The official website for the company is www.archtherapeutics.com. The biotechnology company can be reached via phone at (617) 431-2313 or via email at investors@archtherapeutics.com.

This page (OTCMKTS:ARTH) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial